EGFR-targeting drugs and chemotherapy: a review
Author Information
Author(s): Milano G, Spano J-P, Leyland-Jones B
Hypothesis
What are the interactions between EGFR-targeting drugs and conventional cytotoxic agents?
Conclusion
EGFR-targeting drugs show potential when combined with chemotherapy, but clinical results vary significantly.
Supporting Evidence
- EGFR-targeting drugs have shown encouraging results in preclinical studies.
- Clinical trials often show disappointing results compared to preclinical data.
- Combination therapies can lead to both additive and supra-additive effects.
Takeaway
This study looks at how drugs that target a specific cancer receptor can work better when used with traditional chemotherapy, but sometimes they don't work as well in real patients as they do in lab tests.
Methodology
The review critically examines preclinical and clinical studies on the combination of EGFR-targeting drugs and cytotoxic agents.
Limitations
The review highlights gaps between preclinical findings and clinical outcomes, particularly regarding drug combinations and treatment sequences.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website